153 related articles for article (PubMed ID: 35979578)
1. Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.
Ohno S; Hayashi K; Shimizu R; Ishii A; Tanaka H
J Clin Exp Hematop; 2022 Sep; 62(3):147-153. PubMed ID: 35979578
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
3. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
7. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.
Winkelmann N; Desole M; Hilgendorf I; Ernst T; Sayer HG; Kunert C; Mügge LO; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2603-2610. PubMed ID: 27640002
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma.
Sawazaki A; Sugimori C; Yamaguchi M; Nakao S
Transfus Apher Sci; 2023 Jun; 62(3):103649. PubMed ID: 36739175
[TBL] [Abstract][Full Text] [Related]
9. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
[TBL] [Abstract][Full Text] [Related]
10. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
12. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
[TBL] [Abstract][Full Text] [Related]
13. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
15. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
17. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma.
Knudsen LM; Rasmussen T; Nikolaisen K; Johnsen HE
Eur J Haematol; 2001; 67(5-6):289-95. PubMed ID: 11872076
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
19. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
[TBL] [Abstract][Full Text] [Related]
20. Impact of Hematopoietic Progenitor Cell Count as an Indicator for Optimal Timing of Peripheral Stem Cell Harvest in Clinical Practice.
Tanaka H; Ishii A; Sugita Y; Shimizu R; Sato F; Sakuma Y; Iwai R; Kakuta S
J Clin Exp Hematop; 2017; 56(3):150-159. PubMed ID: 28331129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
